Media
Corgentech Selected to Present at Future Leaders in Biotech Industry Conference
Palo Alto, Calif., April 1, 2003 -- Corgentech Inc., a privately-held biotechnology company, today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Future Leaders in the Biotech Industry Conference. His presentation will be held on Thursday, April 3 from 1:20 to 1:45 p.m. EST, in room 304/305 at the Millennium Broadway Hotel and Conference Center in New York.
McLaughlin will provide an update on the company's progress with its lead product, CGT003, an E2F Decoy drug/device combination, which is being evaluated in two Phase III clinical trials for prevention of graft failure following coronary and peripheral bypass surgery. He will also discuss other projects in the company's expanding pipeline based on its novel and versatile research platform.
"With our lead product, CGT003, Corgentech is in a position to bring to market a first-of-its-kind treatment for an unmet need. We plan to announce data from our two Phase III trials studies in late 2004 and, with Food and Drug Administration fast-track status, we hope to progress expeditiously toward commercialization," said McLaughlin. "Corgentech also has an expanding pipeline based on our proprietary technology platform, including the company's second product, CGT021, which will enter a Phase I/II clinical trial for the prevention of arterio-venous (AV) graft failure in End-Stage Renal Disease (ESRD) patients requiring hemodialysis in the second quarter of this year."
The Future Leaders in Biotech Conference is a forum for select companies "best positioned to provide market leadership" to present to top financial professionals, including institutional investors, investment bankers and sellside analysts. The annual conference is sponsored by BioCentury Publications and Thomson Financial/Carson.
About Corgentech Inc.
Corgentech Inc. is a privately-held biotechnology company that is the leader in the discovery, development and commercialization of an exciting and powerful new class of therapeutics called transcription factor decoys or TF Decoys. The Company's proprietary technology platform is capable of delivering multiple new product candidates to treat diseases that affect large patient populations in a relatively short period of time. Corgentech is based in Palo Alto, Calif. For more information on the company and its technology, visit www.corgentech.com.
| Contacts: | |
| Richard Powers Corgentech |
Kristin Nash WeissCom Partners |
| 650-624-9600 [email protected] |
415-302-7951 [email protected] |
